ArticleScientific reports2025
Improvement in proteinuria attenuates the occurrence of venous thromboembolism: A population-based cohort study.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Proteinuria contributes to venous thromboembolism (VTE), and its levels can change over time. This registry-based retrospective study investigated the association between changes in proteinuria status and VTE occurrence at the population level. We included participants (n = 1,712,507) who underwent two successive health checkups during the initial period (2003 or 2004) and the subsequent period (2005 or 2006). Outcomes were defined as the occurrence of VTE, including deep vein thrombosis, pulmonary thromboembolism, and other venous thromboses, according to the International Classification of Diseases-10 code. A multivariate Cox proportional hazards model was used to assess the occurrence of VTE based on changes in proteinuria. Over a median follow-up period of 14.5 years, 45,711 participants (event rate: 1.88%) experienced a VTE. Compared with the normal group, the incidence risk of VTE dose dependently increased with the severity of proteinuria in each of the persistent, progressed, and improved groups (p for trend < 0.001). In a pairwise comparison, the risk of occurrence of VTE in the improved (hazard ratio [HR]: 1.18, 95% confidence interval [CI]: 1.10-1.27), progressed (HR: 1.31, 95% CI: 1.23-1.40), and persistent groups (HR: 1.88, 95% CI: 1.61-2.19) were higher than that of the normal group. In addition, the improved group had a lower risk of VTE occurrence than that of the persistent group (HR: 0.69, 95% CI: 0.58-0.82, p < 0.001). Our study showed that the incidence risk of VTE was associated with change and severity of proteinuria status. Improvement in proteinuria may attenuate the occurrence of VTE.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.